NASH contender CymaBay runs into trouble as mid-stage data disappoint
A snapshot of negative data from an ongoing 52-week mid-stage NASH study evaluating CymaBay Therapeutics’ lead drug has triggered alarm, after the experimental liver drug, seladelpar, performed worse than a placebo at a three-month readout.
Surprised and aghast, investors of the San Francisco-based biotech wasted little time in registering their disappointment. The company’s shares $CBAY plummeted about 44.5% to $6.16 in early Tuesday trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.